Anti-VEGF Deal Benchmarks in Ophthalmology

Median Upfront

$768M

Range: $423M - $1.1B

Total Deal Value

$3.6B

Range: $2.4B - $4.9B

Royalty Rate

10.2% - 20.4%

Tiered up to 24.4%

Dev Milestones

$569M

Range: $385M - $756M

Model Your Deal

Market Analysis

Anti-VEGF therapies in ophthalmology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,400+ verified transactions, the median upfront payment for a Phase 2 anti-vegf asset in ophthalmology is $768M, with total deal values reaching $3.6B. Development milestones average $569M, while regulatory milestones contribute $712M.

The ophthalmology anti-vegf landscape is characterized by moderate competitive intensity concentrated in retinal disease and dry eye. Gene therapies for inherited retinal diseases, extended-duration intravitreal agents, and topical biologics are expanding the opportunity set. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for anti-vegf ophthalmology deals range from 10.2% to 20.4% at the base tier, with tiered escalation reaching 14.2%-24.4% on blockbuster sales. Commercial milestones averaging $1.6B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a anti-vegf ophthalmology licensing deal?

Based on our analysis, Phase 2 anti-vegf licensing deals in ophthalmology average $768M in upfront payments, with a range of $423M to $1.1B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for anti-vegf ophthalmology transactions?

The median total deal value for Phase 2 anti-vegf assets in ophthalmology is $3.6B, ranging from $2.4B to $4.9B. This includes development milestones ($569M), regulatory milestones ($712M), and commercial milestones ($1.6B).

What royalty rates are standard for anti-vegf deals in ophthalmology?

Base royalty rates for anti-vegf ophthalmology transactions range from 10.2% to 20.4%, with tiered escalations reaching 14.2%-24.4% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in anti-vegf ophthalmology deals?

Anti-VEGF ophthalmology deals allocate approximately 79% of total deal value to milestones. Development milestones ($569M) make up the largest share, followed by commercial milestones ($1.6B) and regulatory milestones ($712M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Ophthalmology

View

Monoclonal Antibody in Ophthalmology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough